Potaczek D P, Undas A, Nowakowski T, Szczeklik A
Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland.
Int Angiol. 2007 Dec;26(4):318-23.
The interleukin-6 (IL-6) -174 G/C polymorphism has been reported to determine IL-6 levels and contribute to the development of cardiovascular disorders. The aim of our study was to evaluate the effect of the IL-6 -174 G/C polymorphism on hemostatic or inflammatory markers in patients with peripheral arterial occlusive disease (PAOD), a common manifestation of obliterative atherosclerosis.
Plasma IL-6, fibrinogen, C-reactive protein (CRP), tissue plasminogen activator, plasminogen activator inhibitor-1 (PAI-1), fibrinopeptide A and intercellular adhesion molecule-1 levels were determined in PAOD patients (n=50) and healthy controls (n=30) genotyped for the IL-6 -174 G/C polymorphism.
In the control group, IL-6, CRP and fibrinogen levels were significantly associated with the IL-6 -174 G/C polymorphism with a gene-dosage effect being the highest in the CC subjects and the lowest in those with the GG genotype (P<0.0001, P=0.0002 and P=0.0001, respectively). Interestingly, the CC homozygotes had lower PAI-1 levels than carriers of the G allele (P=0.04). In PAOD patients, the IL-6 -174 G/C polymorphism had no effect on all the variables measured.
In contrast to apparently healthy subjects, the IL-6 -174 G/C polymorphism showed no association with plasma IL-6, CRP, fibrinogen and PAI-1 levels in PAOD patients.
白细胞介素-6（IL-6）-174 G/C多态性据报道可决定IL-6水平，并促进心血管疾病的发展。我们研究的目的是评估IL-6 -174 G/C多态性对周围动脉闭塞性疾病（PAOD）患者止血或炎症标志物的影响，PAOD是闭塞性动脉粥样硬化的常见表现。
测定了50例PAOD患者和30例健康对照者的血浆IL-6、纤维蛋白原、C反应蛋白（CRP）、组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1（PAI-1）、纤维肽A和细胞间黏附分子-1水平，这些患者和对照者均进行了IL-6 -174 G/C多态性基因分型。
在对照组中，IL-6、CRP和纤维蛋白原水平与IL-6 -174 G/C多态性显著相关，基因剂量效应在CC受试者中最高，在GG基因型受试者中最低（分别为P<0.0001、P=0.0002和P=0.0001）。有趣的是，CC纯合子的PAI-1水平低于G等位基因携带者（P=0.04）。在PAOD患者中，IL-6 -174 G/C多态性对所有测量变量均无影响。
与明显健康的受试者相比，IL-6 -174 G/C多态性与PAOD患者的血浆IL-6、CRP、纤维蛋白原和PAI-1水平无关联。
